The efficacy of gabapentin in migraine prophylaxis: An observational open label study

Acta Clinica Croatica

Volumn 48, Issue 2, 2009, Pages 145-151

  Vuković, Vlasta ^a   Lovrenčić Huzjan, Arijana ^a   Bosnar Puretić, Marijana ^a   Demarin, Vida ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

Headache prevention and control; Headache therapy; Migraine prevention and control; Migraine therapy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GABAPENTIN; LAMOTRIGINE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ADULT; ARTICLE; ATAXIA; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FACE SWELLING; FEMALE; FOLLOW UP; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MOTION; OBSERVATIONAL STUDY; PROPHYLAXIS; SIDE EFFECT; SLOWNESS; SWELLING; TREATMENT DURATION; WEIGHT GAIN;

AMINES; ANTICONVULSANTS; CYCLOHEXANECARBOXYLIC ACIDS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS;

EID: 70649099315     PISSN: 03539466     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. STOVNER LJ, HAGEN K, JENSEN R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007; 27: 193-210.
2. LIPTON RB, LIBERMAN JN, KOLODNER JB, et al. Migraine headache disability and health-related quality of life: a population-based case-control study from England. Cephalalgia 2003; 23: 441-50.
3. EVERS S, AFRA J, FRESE A, GOADSBY PJ, LINDE M, MAY A, members of the Task Force et al. EFNS guidelines on the drug treatment of migraine - report of an EFNS Task Force. Eur J Neurol 2006; 13: 560-72.
4. Ad Hoc Committee for the Diagnostic and Therapeutic Guidelines for Migraine and Cluster Headache. Prophylactic treatment of migraine. J Headache Pain 2001; 2: 147-61.
5. YOON MS, SAVIDOU I, DIENER HC, et al. Evidence-based medicine in migraine prevention. Expert Rev Neurother 2005; 5: 333-41.
6. SILBERSTEIN DS. Preventive treatment of headaches. Curr Opin Neurol 2005; 18: 289-92.
7. DEMARIN V, VUKOVIC V, LOVRENCIC-HUZJAN A, et al. Evidence based guidelines for treatment of primary headaches. Report of the Croatian Neurovascular Society. Acta Clin Croat 2005; 44: 139-83.
8. LODER E, BIONDI D. General principles of migraine management: the changing role of prevention. Headache 2005; 45 (Suppl 1) : S33-S47.
9. ADELMAN JU, ADELMAN LC, Von SEGGERN R. Costeffectiveness of antiepileptic drugs in migraine prophylaxis. Headache 2002; 42: 978-83.
10. SILBERSTEIN SD, GOADSBY PJ. Migraine: preventive treatment. Cephalalgia 2002; 22: 491-512.
11. MAY A, LEONE M, AFRA J, et al. EFNS Task Force. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol 2006; 13: 1066-77.
12. MATHEW NT. Gabapentin in migraine prophylaxis. Cephalalgia 1996; 16: 367. (Abstract)
13. WESSELY P, BAUMGARTNER C, KLINGER D, et al. Preliminary results of a double-blind study with the new migraine prophylactic drug gabapentin. Cephalalgia 1987; 7: 477-8.
14. MATHEW NT, RAPOPORT A, SAPER J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41: 119-28.
15. SPIRA PJ, BERAN RG, Australian Gabapentin Chronic Daily Group. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology 2003; 61: 1753-9.
16. MAGNUS L. Nonepileptic uses of gabapentin. Epilepsia 1999; 40 (Suppl 6) : S66-S72.
17. PORTA-ETESSAM J, BENITO-LEON J, MARTINEZ-SALIO A, et al. Gabapentin in the treatment of SUNCT syndrome. Headache 2002; 42: 523-4.
18. FRANCA MC Jr, COSTA AL, MACIEL JA Jr. Gabapentinresponsive idiopathic stabbing headache. Cephalalgia 2004; 24: 993-6.
19. GARZA I, BLACK D F. Persistent primary thunderclap headache responsive to gabapentin. J Headache Pain 2006; 6: 419-21.
20. TRUCCO M. Nummular headache: another case treated with gabapentin. J Headache Pain 2007; 8: 137-8.
21. nd edition. Cephalalgia 2004; 24 (Suppl 1) : 1-160.
22. SILBERSTEIN SD, LIPTON RB, DODICK DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007; 47: 170-80.
23. STOREY RJ, CALDER CS, HART DE, et al. Topiramate in migraine prevention: a double blind, placebo-controlled study. Headache 2001; 41: 968-75.
24. SILBERSTEIN SD, NETO W, SCHMITT J, et al. MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004; 61: 490-5.
25. HERING R, KURITZKY A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992; 12: 81-4.
26. KLAPPER JA. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997; 17: 103-8.
27. MATHEW NT, SAPER JR, SILBERSTEIN SD, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995; 52: 281-6.
28. FREITAG FG, COLLINS SD, CARLSON HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002; 58: 1652-9.
29. KANIECKI RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol 1997; 54: 1141-5.
30. KINZE S, CLAUSS M, REUTER U, et al. Valproic acid is effective in migraine prophylaxis at low serum levels: a prospective open-label study. Headache 2001; 41: 774-8.
31. DIENER HC, KAUBE H, LIMMROTH V. Antimigraine drugs. J Neurol 1999; 246: 515-9.
32. SILBERSTEIN SD, COLLINS SD. Safety of divalproex sodium in migraine prophylaxis: an open label, long-term study. Long-term Safety of Depakine in Headache Prophylaxis Study Group. Headache 1999; 39: 633-43.
33. EDWARDS KR, GLANTZ MJ, NORTON JA, et al. Prophylactic treatment of episodic migraine with topiramate: a double-blind, placebo-controlled trial in 30 patients. Cephalalgia 2000; 20: 316. (Abstract)
34. YOUNG WB, HOPKINS MM, SHECHTER AL, et al. Topiramate: a case series study in migraine prophylaxis. Cephalalgia 2002; 22: 659-63.
35. SHAYGANNEJAD V, JANGHORBANI M, GHORBANI A, et al. Comparison of the effect of topiramate and sodium valproate in migraine prevention: a randomized blinded crossover study. Headache 2006; 46: 642-8.
36. WIFFEN PJ, McQUAY HJ, REES J, MOORE RA. Gabapentin for acute and chronic pain. Cochrane Database of Systematic Reviews 2005, Issue 3, Art. No. CD005452. DOI: 10.1002/14651858. CD005452
37. D'ANDREA G, GRANELLA F, CADALDINI M, et al. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia 1999; 19: 64-6.
38. PASCUAL J, CAMINERO AB, MATEOS V, et al. Preventing disturbing migraine aura with lamotrigine: an open study. Headache 2004; 44: 1024-8.
39. LAMPL C, KATSARAVA Z, DIENER HC, et al. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry 2005; 76: 1730-2.
40. GUPTA P, SINGH S, GOYAL V, et al. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp). Headache 2007; 47: 402-12.
41. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine. Second Edition. Cephalalgia 2000; 20: 765-86.